196 related articles for article (PubMed ID: 30566038)
21. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
Shimizu W; Antzelevitch C
Circulation; 1997 Sep; 96(6):2038-47. PubMed ID: 9323097
[TBL] [Abstract][Full Text] [Related]
22. Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice.
Fabritz L; Kirchhof P; Franz MR; Nuyens D; Rossenbacker T; Ottenhof A; Haverkamp W; Breithardt G; Carmeliet E; Carmeliet P
Cardiovasc Res; 2003 Mar; 57(4):1085-93. PubMed ID: 12650887
[TBL] [Abstract][Full Text] [Related]
23. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.
Mazzanti A; Maragna R; Faragli A; Monteforte N; Bloise R; Memmi M; Novelli V; Baiardi P; Bagnardi V; Etheridge SP; Napolitano C; Priori SG
J Am Coll Cardiol; 2016 Mar; 67(9):1053-1058. PubMed ID: 26940925
[TBL] [Abstract][Full Text] [Related]
24. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S
Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495
[TBL] [Abstract][Full Text] [Related]
25. The Citrus Flavonoid Hesperetin Has an Inadequate Anti-Arrhythmic Profile in the ΔKPQ Na
Alvarez-Collazo J; López-Requena A; Alvarez JL; Talavera K
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32599724
[TBL] [Abstract][Full Text] [Related]
26. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
Bos JM; Crotti L; Rohatgi RK; Castelletti S; Dagradi F; Schwartz PJ; Ackerman MJ
Circ Arrhythm Electrophysiol; 2019 May; 12(5):e007280. PubMed ID: 31006312
[TBL] [Abstract][Full Text] [Related]
27. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
Priori SG; Cantù F; Schwartz PJ
Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
[TBL] [Abstract][Full Text] [Related]
28. Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
Cashman JR; Ryan D; McKeithan WL; Okolotowicz K; Gomez-Galeno J; Johnson M; Sampson KJ; Kass RS; Pezhouman A; Karagueuzian HS; Mercola M
J Med Chem; 2021 May; 64(9):5384-5403. PubMed ID: 33942619
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Fredj S; Sampson KJ; Liu H; Kass RS
Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
[TBL] [Abstract][Full Text] [Related]
30. Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study.
Hohmann S; Rudic B; Konrad T; Duncker D; König T; Tülümen E; Rostock T; Borggrefe M; Veltmann C
Europace; 2017 Oct; 19(10):1723-1729. PubMed ID: 27915266
[TBL] [Abstract][Full Text] [Related]
31. Effect of mexiletine on long QT syndrome model.
Wang HW; Zheng YQ; Yang ZF; Li CZ; Liu YM
Acta Pharmacol Sin; 2003 Apr; 24(4):316-20. PubMed ID: 12676070
[TBL] [Abstract][Full Text] [Related]
32. A molecular basis for the therapy of the long QT syndrome.
Priori SG; Napolitano C; Schwartz PJ
Arch Mal Coeur Vaiss; 1996 Sep; 89(9):1185-7. PubMed ID: 8952843
[TBL] [Abstract][Full Text] [Related]
33. Structure of human Na
Li Z; Jin X; Wu T; Zhao X; Wang W; Lei J; Pan X; Yan N
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33712541
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel.
Kambouris NG; Nuss HB; Johns DC; Tomaselli GF; Marban E; Balser JR
Circulation; 1998 Feb; 97(7):640-4. PubMed ID: 9495298
[TBL] [Abstract][Full Text] [Related]
35. Intracellular calcium attenuates late current conducted by mutant human cardiac sodium channels.
Potet F; Beckermann TM; Kunic JD; George AL
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):933-41. PubMed ID: 26022185
[TBL] [Abstract][Full Text] [Related]
36. Differential calcium sensitivity in Na
Abdelsayed M; Baruteau AE; Gibbs K; Sanatani S; Krahn AD; Probst V; Ruben PC
J Physiol; 2017 Sep; 595(18):6165-6186. PubMed ID: 28734073
[TBL] [Abstract][Full Text] [Related]
37. Reduced current density, partially rescued by mexiletine, and depolarizing shift in activation of SCN5A W374G channels as a cause of severe form of Brugada syndrome.
Nakajima T; Dharmawan T; Kawabata-Iwakawa R; Tamura S; Hasegawa H; Kobari T; Ota M; Tange S; Nishiyama M; Kaneko Y; Kurabayashi M
Ann Noninvasive Electrocardiol; 2021 May; 26(3):e12828. PubMed ID: 33463855
[TBL] [Abstract][Full Text] [Related]
38. Mexiletine Block of Voltage-Gated Sodium Channels: Isoform- and State-Dependent Drug-Pore Interactions.
Nakagawa H; Munakata T; Sunami A
Mol Pharmacol; 2019 Mar; 95(3):236-244. PubMed ID: 30593458
[TBL] [Abstract][Full Text] [Related]
39. Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.
Priori SG; Napolitano C; Cantù F; Brown AM; Schwartz PJ
Circ Res; 1996 Jun; 78(6):1009-15. PubMed ID: 8635231
[TBL] [Abstract][Full Text] [Related]
40. Indications for mexiletine in the new ESC guidelines and beyond.
Vamos M; Zsigmond EJ; Hohnloser SH
Expert Opin Pharmacother; 2023; 24(12):1403-1407. PubMed ID: 37306465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
